Deciphera Pharmaceuticals Stock Forecast, Price & News

+0.71 (+2.29 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume606,154 shs
Average Volume412,131 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.06 out of 5 stars

Medical Sector

484th out of 1,352 stocks

Pharmaceutical Preparations Industry

239th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

Is Deciphera Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Deciphera Pharmaceuticals stock.
View analyst ratings for Deciphera Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Deciphera Pharmaceuticals?

Wall Street analysts have given Deciphera Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Deciphera Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Deciphera Pharmaceuticals

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its earnings results on Tuesday, August, 3rd. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by $0.06. The company earned $23.57 million during the quarter, compared to analysts' expectations of $22.25 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 50.07% and a negative net margin of 308.58%.
View Deciphera Pharmaceuticals' earnings history

How has Deciphera Pharmaceuticals' stock price been impacted by Coronavirus?

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DCPH shares have decreased by 28.5% and is now trading at $31.75.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DCPH?

6 brokerages have issued twelve-month price targets for Deciphera Pharmaceuticals' shares. Their forecasts range from $60.00 to $78.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $69.67 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Steven L. Hoerter, President, Chief Executive Officer & Director
  • Tucker Kelly, Chief Financial Officer, Treasurer & Executive VP
  • Daniel L. Flynn, Chief Scientific Officer & Executive VP
  • Stephen B. Ruddy, Chief Technical Officer
  • Matthew L. Sherman, Chief Medical Officer & Executive Vice President

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Deciphera Pharmaceuticals' key competitors?

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jefferies Group LLC (0.00%), Redmile Group LLC (7.31%), Vanguard Group Inc. (6.77%), BlackRock Inc. (6.34%), Franklin Resources Inc. (5.27%) and State Street Corp (3.53%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals

Which major investors are selling Deciphera Pharmaceuticals stock?

DCPH stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Franklin Resources Inc., Price T Rowe Associates Inc. MD, FMR LLC, Wells Fargo & Company MN, Emerald Advisers LLC, Goldman Sachs Group Inc., and Redmile Group LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include James Arthur Bristol, and Michael Douglas Taylor.
View insider buying and selling activity for Deciphera Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Deciphera Pharmaceuticals stock?

DCPH stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Logos Global Management LP, CIBC Asset Management Inc, Armistice Capital LLC, BlackRock Inc., State Street Corp, Avoro Capital Advisors LLC, and Point72 Asset Management L.P..
View insider buying and selling activity for Deciphera Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $31.75.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals has a market capitalization of $1.84 billion and generates $42.09 million in revenue each year. The company earns $-266,490,000.00 in net income (profit) each year or ($4.78) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 350 workers across the globe.

What is Deciphera Pharmaceuticals' official website?

The official website for Deciphera Pharmaceuticals is

Where are Deciphera Pharmaceuticals' headquarters?

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.